•Where does AI truly move the needle? From discovery and early R&D through translation toward CMC, manufacturing, and commercial viability—what delivers real impact today, and what still needs to change
•What really limits scale? Data quality, biological validation, regulatory acceptance, talent, and infrastructure—why most bottlenecks sit beyond discovery
•Who wins the 2030s? AI-native platforms vs asset-led companies, and the organisational models that will define long-term advantage
Moderator: Russell Lamontagne, Chief Executive Officer, Boston Immune Technologies
Panellists:
Yashas Kannan, Vice President Drug Discovery, PentaBind
Catherine Stace, Executive Vice President, Kuano
